Process for producing Aliskiren

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9346745
APP PUB NO 20130071899A1
SERIAL NO

13701440

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A new route of synthesis of the compound Aliskiren of formula (I), used in the treatment of hypertension, is described.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CHEMO IBERICA S ABARCELONA LORNA BARCELONA BARCELONA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Banfi, Luca Genoa, IT 2 4
Carcone, Luca Cervaro, IT 8 0
Cini, Elena Gambassi Terme, IT 3 1
Rasparini, Marcello Cura Carpignano, IT 13 8
Riva, Renata Genoa, IT 1 0
Roseblade, Stephen Cambridge, GB 2 0
Russo, Adele Baronissi, IT 1 0
Taddei, Maurizio Monteriggioni, IT 15 27
Vitale, Romina Ovada, IT 1 0
Zanotti-Gerosa, Antonio Carlo Cambridge, GB 1 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 24, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00